Liminatus Pharma, Inc. 8-K — AI Bull & Bear Analysis

Liminatus Pharma is currently fighting for its survival on the Nasdaq Global Market after failing to meet essential market value requirements. While the company has successfully filed an appeal to prevent an immediate trading suspension, the underlying issues—specifically the lack of sufficient market capitalization and public float—remain unresolved. The outcome now hinges on whether management can produce a viable plan to regain compliance or if the delisting process will proceed, fundamentally altering the stock's liquidity and investor profile.